 |
 |
|
|
|
| LACOSAMIDE |
 |
| (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide. |
 |
| 175481-36-4 |
 |
| Lacosamide (LCM) is anticonvulsant in animal models and is in phase 3 assessment for epilepsy and neuropathic pain. Here we seek to identify cellular actions for the new drug and effects on recognised target sites for anticonvulsant drugs. |
 |
DESCRIPTION WHITE TO OFF-WHITE POWDER
IDENTIFICATION IR.
MELTING POINT 140 ~ 143¡É
LOSS ON DRYING NOT MORE THAN 0.5%
RESIDUE ON IGNITION NOT MORE THAN 0.1%
HEAVY METALS NOT MORE THAN 20PPM
ASSAY (HPLC) NOT LESS THAN 98% (C13H18N2O3)
|
| Industrial field |
pharmaceutical |
|
|
 |
 |
|
IFFECT CHEMPHAR CO., LTD
|
| Phone |
+86-755-8376-1610 |
| Fax |
+86-755-8327-9595 |
| Homepage |
- |
| E-mail |
sales3@iffchem.com.cn
|
| Address |
3804-3805, International Science & Technology Building,
No.3007 Shennan Road, Futian Dis. Shenzhen 518033, P.R. China |
|
 |
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
|
|
|
|
